We report a case of recurrent priapism in a sickle cell patient who had undergone physiological transformation from a low-¯ow state to a mixed high-¯owalow-¯ow picture. An oral alphaadrenergic agonistahistamine-1 antagonist combination maintained a balance of potency without stutter in the latter state, whereas an oral alpha-adrenergic agonist in the early part of his course did not prevent priapic progression. Concomitant use of a non-steroidal anti-androgenic agent rendered him impotent despite good libido. Other etiologies should be considered in the setting of recurrent priapism and failed standard therapies; duplex ultrasound is useful in order to delineate the hemodynamics. This case supports contentions that priapism is a spectrum phenomenon, and raises questions regarding the mechanism by which alpha-adrenergic agents prevent priapic progression.
Introduction
Priapism is described as a prolonged erection unaccompanied by sexual desire or stimulation. Sickle cell anemia accounts for approximately 25% of reported cases of priapism. 1 Conversely, the incidence of priapism in sickle cell patients is 38 ± 42% in adults, 2, 3 and up to 64% in children. 4 Many sickle cell patients experience what has been termed stuttering' priapism (brief, intermittent, generally self-limiting priapic episodes). 1 However, over half of these patients have greater than ten episodes, and at least 28% have acute prolonged events, 3, 5 testimony to the challenge this problem presents. Further, the impotency rate in sicklers following prolonged ischemic episodes is 36 ± 56%. 3, 6 Although low-¯ow priapism occurs in nearly 95% of cases of priapism and is the most frequent classi®cation associated with sickle cell disease, 1 cases of idiopathic high-¯ow priapism have also been described in association with sickle cell anemia. 7 ± 9 . Rarely, however, is the hemodynamic state of the event held in question. We report here a complex case of recurring priapism in a patient with sickle cell anemia.
Case report
A 19-year-old black man with sickle cell anemia and no history of trauma presented to the emergency department after multiple recurrent episodes of priapism. This patient had a long history of complications related to his sickle cell disease, including aplastic crisis and cholecystitis. His ®rst episode of priapism was at the age of 12 and recurred daily for three months. The patient received relief from supportive sickle cell therapy, including oxygenation, hydration, and alkalization. Six years later, the patient presented again with recurrent painful erections. This again resolved over several hours with conservative management, this time with the addition of oral pseudoephedrine (an alpha-adrenergic agonist). Since then, the patient presented to the emergency department approximately twice per week with recurrent priapic episodes while using oral pseudoephedrine. Each episode lasted approximately 2 h per day, usually with onset in the twilight hours. Throughout his course he had intercourse regularly with appropriate detumescence, however, some of these erections also progressed to major priapic episodes. He failed multiple hypertransfusion treatments and a 4 month trial of hydroxyurea. Hemoglobin electrophoresis typically revealed the HbS concentration to be over 60% of his overall hemoglobin content. Exchange transfusions were begun in order to lower the HbS concentration, and he gained short-term relief.
The patient's recurring bouts of priapism eventually worsened, ultimately requiring corporal irrigations with phenylephrine injections. Typically, as much as 300 cm 3 of dark sludged blood was aspirated each time. Intracorporal phenylephrine injection worked immediately at doses of 500 mg to cause near total¯accidity, though his penis continued to appear edematous and pulsatile.
Cavernosal blood gas values during a subsequent priapism event were pH 7.39, pO 2 40.2, pCO 2 54.4, and O 2 sat 89%. Following intracavernous phenylephrine injection, a duplex non-color Doppler ultrasound of the patient's semi-¯accid penis was performed. It revealed patent cavernosal arteries with a diameter of 1.3 mm, peak systolic velocity (PSV) of 0.75 mas, and end-diastolic velocity of 0.18 mas, all consistent with high-¯ow priapism, though no A-V ®stula was appreciated. He was then begun on Casodex 1 (bicalutamide, a non-steroidal anti-androgen, 50 mg po qd) and Ornade 1 (phenylpropanolamine 75 mgachlorpheniramine 12 mg, an alpha-adrenergic agonist and H1 antagonist, 1 po bid) to which he reported relief. The patient subsequently stopped using bicalutamide due to impotence (despite good libido), yet remained priapism free with phenylpropanolamineachlorpheniramine alone. He later substituted Contac 1 (phenylpropanolamine 75 mgachlorpheniramine 8 mg, 1 po bid) for Ornade 1 as a matter of availability, and continued to remain priapism free for three weeks. The patient's compliance then wavered, and a major episode of priapism ensued in the absence of any medication at all. He was hospitalized again, though he refused angiography in fear of the potential for impotence associated with the procedures that might have followed. He underwent corporal irrigationsaphenylephrine injections daily, and bicalutamide and phenylpropanolamineachlorpheniramine were restarted. Relief of priapism was noted by day ®ve when the patient was discharged. The patient remained priapism-free and had painless intercourse regularly while using phenylpropanolamineachlorpheniramine at home for eight months until he presented to the Emergency Department (ED) in sickle cell crisis. In the ED the patient's CasodexaOrnade protocol was discontinued, and he subsequently developed priapism. The patient regained his priapism-free state when Casodex and Ornade (or Contac) were continued.
Discussion
Central to this case is an understanding of the classi®cations of priapism. There are two main categories: high-¯ow (non-ischemic) and low-¯ow (ischemic); though it has been suggested that a spectrum of states exists between the two, 10 dependent upon the number of emissary veins involved, severity of the disease process and duration of venous occlusion. 11 High-¯ow priapism is characterized by adequate (or increased) arterial in¯ow with normal venous out¯ow, but helicine arteriolar bypass, or a defect in their regulation, prevents detumescence. 8 ± 12 Typically there is a history of direct penile or perineal trauma with immediate onset of priapism, the result of an arterio-venous ®stula, though signi®cant delays (months) may occur. In the absence of trauma, it is considered idiopathic, however, as mentioned earlier, there are several reports of high-¯ow in association with sickle cell disease. 7 ± 9 In general, penile blood gases have arterial values, and corporal aspiration or injection with alpha-adrenergic agonists usually results in only a partial and temporary detumescence. 12 It is best treated by angiographic embolization; surgical ligature of the pudendal or cavernosal artery is another option. 13 Low-¯ow priapism is much more common, and is the state found in virtually all of those with sickle cell disease. It is thought to be the result of venoocclusion and vascular stasis which, in turn, results in tissue hypoxia. The ischemia renders it painful, and aspirated penile blood is dark in color. It has been de®ned by corporal blood gas values of pH`7.25, pO 2`3 0, and pCO 2 b 60. 14 Various theories have been invoked to explain the initiation of red blood cell (RBC) sickling and sludging of blood, including the relatively acidic state of the corpora cavernosa during erection, mild acidosis accompanying hypoventilation during sleep, and abnormal endothelial adherence. 14 In those with sickle cell associated priapism, conservative sickle cell management is usually suf®cient; exchange transfusion therapy is often warranted; and corporal aspirationaalpha-agonist injection and surgical shunting procedures are reserved for the most refractory cases.
Early priapic episodes experienced by this patient were typical of the low-¯ow state as classically described. The patient was allieved of his painful, complete, bicorporal erection by conservative sickle cell management, aimed at the veno-occlusive phenomenon. Eventually the priapic bouts became resistant to the once effective therapies, and in the most recent episodes, clearly exhibited high-¯ow traits, however, tempered by low-¯ow qualities as well. Doppler ultrasound studies of the normal organ typically show cavernous arterial diameter of the order of 1.2 mm following alprostadil injection. 15 It has been the experience in our clinics and others 16 that non-stimulated patients typically have diameters on the order of 0.3 mm, and dilate to 1 mm following Trimix (papaverineaphentolaminea prost-aglandin E1) or PGE1 intracavernosal injection. In this patient, ultrasound demonstrated a cavernosal arterial diameter of 1.3 mm following direct injection with a vasoconstrictor. Further, systolic blood¯ow was high at 0.75 mas (normal Priapism of ambiguous classi®cation in sickle cell S Hoffman et al during arti®cial erection is 0.44 mas), 15 and the functional response to phenylephrine intra-corporal injection was immediate and incomplete (also typical of high-¯ow states). The corporal blood gas, however, was ambiguous, neither strictly arterial nor ischemic in character. Had this been a uniformly high-¯ow episode, the patient would likely have had a painless, partially erect penis. Also, the pulsatile action of his organ in the incompletely detumesced state with end-diastolic¯ow suggests persistent partial, though signi®cant, veno-occlusion. (The normal, fully erect penis has pulsatile action and is associated with no end-diastolic¯ow. End-diastolic¯ow is seen only in the partially rigid state when venous out¯ow remains competent, however, pulsatile action is not normally seen in this phase. 15 Whether veno-occlusion here is a result of the duration of his priapism or a consequence of RBC sickling is unclear. Nevertheless, it seems that this patient's latter episodes exhibited characteristics of both high-and low-¯ow priapism. The varied responses of this patient to medical management raise interesting pharmacological and pathophysiological questions. Virag et al, 5 demonstrated the prophylactic utility of an oral alphaadrenergic agonist, etilefrine, in six sickle cell patients with stuttering priapism. They also demonstrated the utility of adjuvant self-administered intracorporal injection of the same in the event of breakthrough priapism. 5 These agents are known to cause corporal smooth muscle contraction and vasoconstriction, and therefore work directly and indirectly on both in¯ow and out¯ow aspects of penile detumescence. It is striking that the use of alpha agonists here did not work early in this patient's course when his clinical picture was that of low-¯ow priapism, whereas he had no priapic events in the presence of alpha agonists later in his course when the picture was mixed. This not only gives credence to the point that this patient underwent a physiological transformation, it supports contentions that the hemodynamics of priapism is a spectrum phenomenon. This issue of spectrum was recently addressed in two case reports of recurrent non-sickle cell related priapism, 10 indicating that the phenomenon is ubiquitous, rather than unique to sickle cell disease.
The pattern of ef®cacy of alpha agonists throughout this patient's course also suggests that of the three primary mechanisms by which erection manifests (arteriolar dilation, corporal smooth muscle relaxation, and venous constriction), 17 alpha-adrenergic agonists work most importantly on the arteriolar aspect. (Note, the fact that beta 2-adrenergic agonists detumesce priapic organs despite the smooth muscle relaxation that they cause 18 highlights that there are other mechanisms, not yet elucidated, which are at least as important to net hemodynamics). Nevertheless, a duplex color Doppler ultrasound of the penis and perineum, before and after phenylephrine injection, would have been useful here for its capacity to show the arteriolar detail. 15 Also from a diagnostic perspective, selective arteriography might have been useful to show an otherwise missed arterio-venous ®stula.
To whatever extent histamine may contribute to penile erection, the pharmacological picture is clouded here by the concomitant use of chlorpheniramine, an H1 antagonist. There is evidence, however, that H1 antagonists actually potentiate histamine-induced corporal smooth muscle relaxation, and that the effects of histamine are mediated by either H2 receptor activation, or yet another uncharacterized receptor. 19 Thus, it is unlikely that the use of chlorpheniramine contributed to the ef®cacy of Ornade 1 or Contac 1 here, though it creates a segue to deeper laboratory investigation.
The rationale for androgen deprivation lies in the notion that stuttering priapism often begins with the erections of rapid eye movement (REM) sleep, 2, 20 and that nocturnal penile tumescence (NPT; that is, spontaneous erections) are testosterone dependent. 21 In the sickle cell study by Emond et al, 3 53 of 54 patients initiated stuttering in association with sleep; and 61% of major priapic episodes were preceded by stuttering. Also, Burnett and co-workers 22 demonstrated that total NPT time per REM sleep time exceeds normal, as does total NPT time, and detumescence time for patients with sickle cell disease. 22 Whether such cycling is a causative risk factor, or an express manifestation of subclinical stuttering, this suggests that efforts at eliminating NPT might prevent stuttering and priapic progression. This is the ®rst report that we are aware of whereby bicalutamide has been used for the purposes of stuttering prophylaxis, though it was used in combination with phenylpropanolamineachlorpheniramine, and caused erectile dysfunction. Flutamide, another non-steroidal anti-androgenic agent, has been used in the setting of sickle cell stuttering priapism, however, only for purposes of inhibiting testosterone¯are reactions during the initiation of goserelin (GnRH analogue) therapy. 23 Their patient had loss of nocturnal penile tumescence and was spared of further priapic events. Unfortunately, goserelin rendered him impotent despite good libido. 23 The use of leuprolide (another GnRH analogue) on the other hand successfully stayed stuttering and progression in a patient without sickle cell disease, without loss in libido or erectile function. 24 Similarly, experience with diethylstilbestrol has shown ef®cacy in the sickle cell stuttering population, however, this drug needs to be titrated very carefully in order to avoid impotency and the various effeminating in¯uences. 25 Thus, while androgen deprivation therapy can be useful in the prevention of priapism in this population, the residual potency can be quite variable (which is the known experience with prostate cancer patients). 26 Priapism of ambiguous classi®cation in sickle cell S Hoffman et al Nevertheless, we report here the ®rst successful use of a non-steroidal anti-androgenic agent as the primary treatment for sickle cell patients to stay priapism and prevent stutter.
Conclusion
We have reported on a case of recurrent priapism in a sickle cell patient who underwent physiological transformation from a low-¯ow state to a mixed high-¯owalow-¯ow picture. While it is reasonable to assume a sickle cellalow-¯ow etiology in these patients, it is important to never lose sight of the other potential causes (see Table 1 ), particularly if there is a change in the pattern of presentation or management requirements. We conjecture that whether this patient's high-¯ow element was idiopathic or iatrogenic (from repeat traumatic needling of his corpora), it exacerbated his already high predisposition to the pooling of blood within his organ, and gives foundation to contentions that priapism is a spectrum phenomenon. It is interesting that the addition of a non-steroidal antiandrogenic agent to his regimen cured him of priapism though rendered him temporarily impotent, and that an oral alpha-adrenergic agonista histamine-1 antagonist combination maintained a balance of potency without stutter. This case further solidi®es the role non-steroidal anti-androgenic agents have in treating priapism. It also brings question to the mechanism of action by which alpha-adrenergic agonists, and possibly histamine antagonists, work to prevent this phenomenon. Priapism of ambiguous classi®cation in sickle cell S Hoffman et al
